Praxis Precision Medicines (NASDAQ: PRAX) COO gets new equity awards

Rhea-AI Filing Summary

Praxis Precision Medicines, Inc. (PRAX) Chief Operating Officer Megan Sniecinski reported new equity awards and a tax-related share withholding. On January 8, 2026, she was granted 9,625 restricted stock units, each representing one share of common stock, vesting in equal annual installments over four years beginning on the one-year anniversary of January 8, 2026. Also on that date, she received a stock option for 7,700 shares at an exercise price of $294.38 per share, with 25% vesting on January 8, 2027 and the remaining 75% vesting in 36 monthly installments.

On January 10, 2026, 1,087 shares of common stock were withheld at a price of $288.45 per share to cover tax obligations tied to previously reported restricted stock unit vesting. After these transactions, she directly held 29,415 shares of common stock and 7,700 stock options.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Sniecinski Megan

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	1,087	$288.45	$314K
Grant/Award	Stock Option (Right to Buy)	7,700	$0.00	--
Grant/Award	Common Stock	9,625	$0.00	--

Holdings After Transaction: Common Stock — 29,415 shares (Direct); Stock Option (Right to Buy) — 7,700 shares (Direct)

Footnotes (1)

1. Ms. Sniecinski was awarded 9,625 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The restricted stock units vest in equal annual installments over a four-year period beginning on the one-year anniversary of the vesting commencement date of January 8, 2026. The restricted stock units may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Shares withheld by the Issuer to satisfy the tax withholding obligations in connection with the vesting of certain previously reported restricted stock units. The shares underlying this stock option vest over a four-year period, with 25% vesting on January 8, 2027 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service through each vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sniecinski Megan

(Last) (First) (Middle)

C/O PRAXIS PRECISION MEDICINES, INC.

99 HIGH STREET, 30TH FLOOR

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Praxis Precision Medicines, Inc. [ PRAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/08/2026		A(1)		9,625	A	$0	30,502	D
Common Stock	01/10/2026		F(2)		1,087	D	$288.45	29,415	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$294.38	01/08/2026		A		7,700		(3)	01/08/2036	Common Stock	7,700	$0	7,700	D

Explanation of Responses:

1. Ms. Sniecinski was awarded 9,625 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The restricted stock units vest in equal annual installments over a four-year period beginning on the one-year anniversary of the vesting commencement date of January 8, 2026. The restricted stock units may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

2. Shares withheld by the Issuer to satisfy the tax withholding obligations in connection with the vesting of certain previously reported restricted stock units.

3. The shares underlying this stock option vest over a four-year period, with 25% vesting on January 8, 2027 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service through each vesting date.

Remarks:

	/s/ Alex Nemiroff, as Attorney-in-Fact	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PRAX COO Megan Sniecinski report?

Megan Sniecinski, Chief Operating Officer of Praxis Precision Medicines (PRAX), reported a grant of restricted stock units, a stock option award, and a tax-related share withholding in common stock.

How many Praxis (PRAX) restricted stock units were granted to the COO?

On January 8, 2026, the COO was granted 9,625 restricted stock units, each representing the right to receive one share of Praxis common stock, vesting in equal annual installments over four years starting one year after January 8, 2026.

What are the terms of the stock options reported for PRAX COO Megan Sniecinski?

She received a stock option for 7,700 shares of Praxis common stock with an exercise price of $294.38 per share. The option vests over four years, with 25% vesting on January 8, 2027 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service.

Why were 1,087 PRAX shares disposed of at $288.45?

The 1,087 shares of Praxis common stock at $288.45 per share were withheld by the issuer on January 10, 2026 to satisfy tax withholding obligations related to the vesting of previously reported restricted stock units.

How many Praxis common shares does the COO hold after these transactions?

Following the reported transactions, the COO beneficially owned 29,415 shares of Praxis common stock directly, along with 7,700 stock options.

How do the PRAX restricted stock units for the COO settle?

The 9,625 restricted stock units may be settled only by delivering shares of Praxis common stock, and the grant is reported in the non-derivative table in line with SEC guidance.